evidence card · statins_dementia_alzheimers_prevention
Statins reduce dementia and Alzheimer's disease risk
H3
≈ mixed
stakes high
3 posts scored
·
across 1 account
·
4 sources
Summary
Large observational meta-analyses report ~20% lower dementia and ~30% lower Alzheimer's incidence among statin users, but this evidence is confounded by healthy-user bias, indication bias, and survivor effects. Dedicated RCTs (HPS, PROSPER) found no cognitive benefit from statins vs placebo over 3-5 years. Major guidelines (AHA/ACC, NICE, USPSTF) do not recommend statins for dementia prevention; the FDA label notes reversible cognitive effects as a possible adverse event. The specific '22% dementia, 32% Alzheimer's' figures come from observational meta-analyses and should not be presented as established causal effects. Evidence is mixed/emerging rather than settled consensus.
Five-score assessment
Scores not yet assigned for this card. (Legacy card; will be populated on next refinement.)
Scope
Population
adults on statin therapy, primarily observational cohorts
Intervention
statin therapy (any type, any dose) for cognitive outcomes
Outcome
incident dementia, Alzheimer's disease, cognitive decline
Not supported for
- prevention of cardiovascular events (covered by statins_primary_high_risk and statins_reduce_cv_secondary)
- treatment of established dementia
- cognitive enhancement in healthy adults